Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Bio-Techne Corp.

NAS: TECH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Bio-Techne Corp.

After Hours

 --Quotes are delayed by 20 min

Mar 2, 2021, 4:15 p.m.

TECH
/zigman2/quotes/203973516/composite

$

375.44

Change

0.00 0.00%

Volume

Volume 12,609

Quotes are delayed by 20 min

/zigman2/quotes/203973516/composite

Previous close

$ 372.44

$ 375.44

Change

+3.00 +0.81%

Day low

Day high

$370.42

$377.13

Open

52 week low

52 week high

$155.17

$414.99

Open

Company Description

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures...

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Valuation

P/E Current

64.06

P/E Ratio (with extraordinary items)

85.79

P/E Ratio (without extraordinary items)

45.42

Price to Sales Ratio

14.09

Price to Book Ratio

7.35

Price to Cash Flow Ratio

50.70

Enterprise Value to EBITDA

43.76

Enterprise Value to Sales

14.31

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

321,170.00

Income Per Employee

99,597.00

Receivables Turnover

5.68

Total Asset Turnover

0.36

Liquidity

Current Ratio

4.88

Quick Ratio

3.92

Cash Ratio

2.54

Profitability

Gross Margin

61.81

Operating Margin

21.26

Pretax Margin

37.43

Net Margin

31.01

Return on Assets

11.31

Return on Equity

17.99

Return on Total Capital

9.01

Return on Invested Capital

13.28

Capital Structure

Total Debt to Total Equity

31.39

Total Debt to Total Capital

23.89

Total Debt to Total Assets

20.63

Long-Term Debt to Equity

29.79

Long-Term Debt to Total Capital

22.68

Officers and Executives

Name Age Officer Since Title
Mr. Charles R. Kummeth 58 2013 President, Chief Executive Officer & Director
Mr. James T. Hippel 48 2014 CFO & Principal Accounting Officer
Dr. Robert Monroe - 2018 Chief Medical Officer
Mr. Kim Kelderman - 2018 President-Diagnostics & Genomics
Ms. Brenda Swierenga Furlow 61 2014 Secretary, Senior Vice President & General Counsel

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/16/2021 Charles R. Kummeth
Chief Executive Officer; Director 		17,428   Derivative/Non-derivative trans. at $411 per share. 7,162,908
02/16/2021 Charles R. Kummeth
Chief Executive Officer; Director 		30,000   Derivative/Non-derivative trans. at $94.35 per share. 2,830,500
02/12/2021 James T. Hippel
Chief Financial Officer 		600   Disposition at $401.52 per share. 240,912
02/12/2021 James T. Hippel
Chief Financial Officer 		9,400   Disposition at $400.32 per share. 3,763,008
02/12/2021 Brenda Swierenga Furlow
SVP - General Counsel 		3,326   Disposition at $399.12 per share. 1,327,473
02/12/2021 Brenda Swierenga Furlow
SVP - General Counsel 		6,674   Disposition at $398.4 per share. 2,658,921
02/12/2021 James T. Hippel
Chief Financial Officer 		10,000   Derivative/Non-derivative trans. at $106.59 per share. 1,065,900
02/12/2021 Brenda Swierenga Furlow
SVP - General Counsel 		10,000   Derivative/Non-derivative trans. at $106.59 per share. 1,065,900
02/08/2021 Roeland Nusse
Director 		6,000   Disposition at $385.08 per share. 2,310,480
02/08/2021 Roeland Nusse
Director 		5,000   Derivative/Non-derivative trans. at $66.9 per share. 334,500
02/08/2021 Roeland Nusse
Director 		1,000   Derivative/Non-derivative trans. at $70.35 per share. 70,350
02/05/2021 Norman David Eansor
President-Protein Sciences 		1,100   Disposition at $385.59 per share. 424,149
02/05/2021 Norman David Eansor
President-Protein Sciences 		1,900   Disposition at $384.15 per share. 729,885
02/05/2021 Norman David Eansor
President-Protein Sciences 		3,700   Disposition at $382.6 per share. 1,415,620
02/05/2021 Norman David Eansor
President-Protein Sciences 		2,900   Disposition at $381.52 per share. 1,106,408
02/05/2021 Norman David Eansor
President-Protein Sciences 		12,833   Disposition at $380.5 per share. 4,882,956
02/05/2021 Norman David Eansor
President-Protein Sciences 		4,500   Disposition at $379.62 per share. 1,708,290
02/05/2021 Norman David Eansor
President-Protein Sciences 		6,000   Disposition at $378.29 per share. 2,269,740
02/05/2021 Kim Kelderman
Pres. Diagnostics & Genom 		823   Disposition at $388.45 per share. 319,694
02/05/2021 Norman David Eansor
President-Protein Sciences 		18,819   Derivative/Non-derivative trans. at $106.59 per share. 2,005,917
02/05/2021 Norman David Eansor
President-Protein Sciences 		14,114   Derivative/Non-derivative trans. at $106.59 per share. 1,504,411
01/15/2021 Charles R. Kummeth
Chief Executive Officer; Director 		20,000   Disposition at $344 per share. 6,880,000
01/11/2021 James T. Hippel
Chief Financial Officer 		2,009   Disposition at $334.98 per share. 672,974
01/11/2021 James T. Hippel
Chief Financial Officer 		3,990   Disposition at $334.39 per share. 1,334,216
01/11/2021 James T. Hippel
Chief Financial Officer 		2,501   Disposition at $333.23 per share. 833,408
01/11/2021 James T. Hippel
Chief Financial Officer 		700   Disposition at $331.61 per share. 232,127
01/11/2021 James T. Hippel
Chief Financial Officer 		400   Disposition at $330.26 per share. 132,104
01/11/2021 James T. Hippel
Chief Financial Officer 		400   Disposition at $328.68 per share. 131,472
01/11/2021 James T. Hippel
Chief Financial Officer 		10,000   Derivative/Non-derivative trans. at $106.59 per share. 1,065,900
12/07/2020 Charles R. Kummeth
Chief Executive Officer; Director 		5,000   Disposition at $308 per share. 1,540,000
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel 		707   Disposition at $302.82 per share. 214,093
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel 		6,783   Disposition at $302.15 per share. 2,049,483
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel 		3,367   Disposition at $301.32 per share. 1,014,544
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel 		938   Derivative/Non-derivative trans. at $106.59 per share. 99,981
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel 		10,857   Derivative/Non-derivative trans. at $106.59 per share. 1,157,247
11/18/2020 Robert V. Baumgartner
Director 		5,000   Disposition at $303.34 per share. 1,516,700
11/18/2020 Robert V. Baumgartner
Director 		5,000   Derivative/Non-derivative trans. at $66.9 per share. 334,500
11/11/2020 James T. Hippel
Chief Financial Officer 		1,100   Disposition at $307.78 per share. 338,558
11/11/2020 James T. Hippel
Chief Financial Officer 		6,291   Disposition at $306.93 per share. 1,930,896
11/11/2020 James T. Hippel
Chief Financial Officer 		7,391   Derivative/Non-derivative trans. at $106.59 per share. 787,806
/news/latest/company/us/tech

MarketWatch News on TECH

  1. Bio-Techne upgraded to buy from hold at Stifel Nicolaus

    7:35 a.m. Feb. 23, 2021

    - Tomi Kilgore

  2. Bio-Techne stock price target raised to $400 from $310 at Stifel Nicolaus

    7:27 a.m. Feb. 3, 2021

    - Tomi Kilgore

  3. Bio-Techne started at sector weight with $340 stock fair value estimate at KeyBanc Capital

    6:28 a.m. Nov. 10, 2020

    - Tomi Kilgore

  5. Bio-Techne downgraded to hold from buy at Stifel Nicolaus

    5:49 a.m. May 27, 2020

    - Tomi Kilgore

  6. Bio-Techne started at buy with $290 stock price target at Benchmark

    5:25 a.m. May 14, 2020

    - Tomi Kilgore

  7. The Investment Allure of American Water Works

    9:30 p.m. Jan. 10, 2020

    - Barron's Online

  8. How to profit from the ‘best of both worlds’ in stock investing

    9:20 a.m. Sept. 23, 2019

    - Philip van Doorn

  9. The Best Mutual Funds You’ve Never Heard Of

    4:28 p.m. July 12, 2019

    - Barron's Online

  11. Five Ways to Play a Growing Health Sector

    12:40 a.m. Jan. 19, 2019

    - Barron's Online

  12. Bio-Techne stock value estimate raised to $180 from $148 at Janney

    1:01 p.m. Aug. 9, 2018

    - Tomi Kilgore

  13. These two trends will continue to power small-cap stocks

    6:50 a.m. July 19, 2018

    - Philip van Doorn

  14. 3 Growth Stocks for the Long Haul

    12:08 p.m. March 7, 2018

    - Barron's Online

  16. What Happened In Pharma Last Quarter?

    8:19 a.m. Aug. 18, 2017

    - Barrons Blogs

  17. Bio-Techne downgraded to neutral from buy at Janney

    6:56 a.m. March 27, 2017

    - Tomi Kilgore

  18. Bio-Techne started at buy with $115 stock price target at Deutsche Bank

    8:45 a.m. Jan. 18, 2017

    - Tomi Kilgore

  20. Tech Data expects deal to add to adjusted EPS in the first year after closing

    6:02 a.m. Sept. 19, 2016

    - Tomi Kilgore

  21. Loading more headlines...
/news/nonmarketwatch/company/us/tech

Other News on TECH

  1. Stifel upgrades Bio-Techne to buy from hold, boosts price target

    10:57 a.m. Feb. 23, 2021

    - Seeking Alpha

  2. Bio-Techne signs a license agreement with Luminary Therapeutics

    7:19 a.m. Feb. 23, 2021

    - Seeking Alpha

  3. Tracking Ron Baron's BAMCO Portfolio - Q4 2020 Update

    10:32 p.m. Feb. 21, 2021

    - Seeking Alpha

  5. 10-Q: BIO-TECHNE CORP

    6:33 a.m. Feb. 8, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  7. Bio-Techne FQ2 2021 Earnings Preview

    12:32 p.m. Feb. 1, 2021

    - Seeking Alpha

  10. Tracking Ron Baron's BAMCO Portfolio - Q3 2020 Update

    5:20 a.m. Dec. 22, 2020

    - Seeking Alpha

  12. 10-Q: BIO-TECHNE CORP

    6:34 a.m. Nov. 9, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  14. Bio-Techne Q1 2021 Earnings Preview

    12:17 p.m. Nov. 4, 2020

    - Seeking Alpha

  15. Notable earnings before Thursday's open

    12:09 p.m. Nov. 4, 2020

    - Seeking Alpha

  16. Abcam Seeks U.S. Investment For Growth Focus

    12:41 p.m. Oct. 19, 2020

    - Seeking Alpha

  18. 5 Tips for Making Money in Penny Stocks

    4:55 p.m. Oct. 7, 2020

    - InvestorPlace.com

  20. Bio-Techne opens new GMP manufacturing facility

    6:19 a.m. Sept. 30, 2020

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Bio-Techne Corp.

614 McKinley Place NE

Minneapolis, Minnesota 55413-2610

Phone

1 6123792956

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

06/2021

View SEC Filings

Revenue

$738.69M

Net Income

$229.07M

2020 Sales Growth

3.5%

Employees

2,300

Annual Report for TECH

/news/pressrelease/company/us/tech

Press Releases on TECH

  4. Bio-Techne To Present At The Barclays Global Healthcare Conference

    7:00 a.m. March 2, 2021

    - PR Newswire - PRF

  21. Loading more headlines...
Link to MarketWatch's Slice.